-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On November 29, Junshi Bio announced that the clinical trial application for Aurora A inhibitor WJ05129 tablets (JS112) of Suzhou Junjing Bio (which jointly invested with Weijing Bio) has been accepted by NMPA
Aurora A, a member of the serine/threonine protein kinase in the Aurora kinase family, plays an important role in the process of cell mitosis
JS112 is an oral small-molecule Aurora A inhibitor, which has a synthetic lethal effect with RB1 gene deletion or inactivation, and can be used to treat malignant tumors with RB1 deletion or inactivation such as small cell lung cancer and triple-negative breast cancer
At present, there is no Aurora A inhibitor approved for marketing in the world
Medicine Rubik's Cube NextPharma
In China, in October this year, the clinical application for the Aurora A inhibitor VIC-1911 of Jisi Yingda was accepted by the NMPA
Note: The original text has been deleted